Press Releases

German Diabetes Society Releases Statement Regarding GI Dynamics’ Termination of U.S. ENDO Trial

Interim analysis of trial data demonstrates statistically significant benefit of EndoBarrier Therapy in reducing blood sugar levels LEXINGTON, Mass. & SYDNEY–29 September 2015–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID), a medical device company that provides innovative...

read more

GI Dynamics, Inc. Announces Corporate Restructuring

LEXINGTON, Massachusetts & SYDNEY, Australia – 21 August 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced that it is reducing headcount by approximately 46% as part of its efforts to...

read more

Appendix 4C Quarterly Report Quarter Ended 30 June 2015

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 July 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 June...

read more

GI Dynamics Concludes ENDO Trial

A review of interim results to follow   Conference call at 9:00 a.m. AEST on 31 July 2015 (7:00 p.m. EDT on 30 July 2015) LEXINGTON, Massachusetts & SYDNEY, Australia – 30 July 2015 – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for...

read more

New Data Presented at ADA Demonstrate Early Effect of EndoBarrier Therapy on Glucose Control and Bile Acid Regulators

Oral and poster presentations at American Diabetes Association annual meeting reinforce value of duodenal-jejunal exclusion for treating type 2 diabetes and obesity June 08, 2015 08:30 AM Eastern Daylight Time LEXINGTON, Mass. & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID),...

read more

2015 Annual Meeting of Stockholders Access for Participants by Webcast and Conference Call

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 27 May 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company) will hold its 2015 Annual Meeting of Stockholders on Tuesday, June 9, 2015 at 9:00 a.m. Australian Eastern Standard Time (which is 7:00 p.m. on Monday, June 8,...

read more

GI Dynamics Announces Results of First Comparative Study of Gastric Bypass and EndoBarrier® Therapy on Diabetes Remission at Digestive Disease Week 2015

LEXINGTON, Mass. & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID), a medical device company providing innovative treatments for type 2 diabetes and obesity, today announced data showing improvement in glucose metabolism following treatment with EndoBarrier® Therapy...

read more

Appendix 4C Quarterly Report Quarter Ended 31 March 2015

LEXINGTON, Massachusetts, United States and SYDNEY, Australia–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the...

read more

ENDO Trial Placed on Enrollment Hold

LEXINGTON, Mass & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced today that the U.S. Food and Drug Administration (FDA) has placed a hold on...

read more

Appendix 4C Quarterly Report Quarter ended 31 December 2014

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 January 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended...

read more